AbbVie
NYSE:ABBV Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 436 Fair Values set on narratives written by author
WA
Consensus Narrative from 27 Analysts
Neuroscience And Oncology Breakthroughs Fuel Revenue Surge And Profit Growth
Key Takeaways The integration of Cerevel Therapeutics and advancements in neuroscience and oncology are set to boost AbbVie's long-term revenue and margins. Growth in immunology and aesthetic segments, with products like SKYRIZI and BoNT/E, will support revenue increase and market penetration.
View narrativeUS$199.97
FV
1.9% undervalued intrinsic discount6.16%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
75users have followed this narrative
21 days ago author updated this narrative